Bayer reports positive results for blood thinner after 2023 setback

Core Insights - German pharma company Bayer reported positive study results for its anticoagulant asundexian, marking a significant turnaround after a research setback two years ago [1] Company Summary - Bayer's asundexian has shown promising results in recent studies, indicating potential for the blood thinner candidate to succeed in the market [1]